External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home Haematology AAMDSIF 2025
Roche and Genentech at

AAMDSIF 2025

March 06 - March 07
Maryland, USA
aamdsif.org
Add to calendar
Share feedback
Share page
-
Medical Materials
Agenda
Coming soon

Sign up or login to unlock the full suite of MEDICALLY features
Mar 6 / Roche and Genentech
Phase III Randomized COMMODORE 1 Trial: 2-Year Safety and Efficacy of Crovalimab▼ in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Switched From Eculizumab
At the primary analysis, the global, randomized, Phase III COMMODORE 1 study showed that crovalimab▼ was well tolerated and had similar exploratory efficacy in patients with paroxysmal nocturnal hemoglobinuria who switched from eculizumab to crovalimab▼ compared with those who continued receiving eculizumab. This poster reports long-term efficacy and safety data from COMMODORE 1, with a median follow-up duration of 2 years.
Haematology Paroxysmal Nocturnal Hemoglobinuria AAMDSIF-2025

Sign up or login to unlock the full suite of MEDICALLY features
Mar 6 / Roche and Genentech
Phase III Randomized COMMODORE 2 Trial: 2-Year Efficacy and Safety of Crovalimab▼ in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Naive to Complement Inhibition
At the primary analysis, the global, randomized, Phase III COMMODORE 2 study demonstrated the non-inferior efficacy of crovalimab▼ vs eculizumab for co-primary efficacy endpoints of hemolysis control and transfusion avoidance in patients naive to complement inhibition, with a comparable safety profile. This poster reports long-term efficacy and safety data from COMMODORE 2, with a median follow-up duration of 2 years.
Haematology Paroxysmal Nocturnal Hemoglobinuria AAMDSIF-2025

Sign up or login to unlock the full suite of MEDICALLY features
Mar 6 / Roche and Genentech
Phase III COMMODORE 1 Trial: 2-Year Efficacy and Safety of Crovalimab▼ (Crova) in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Switched from Ravulizumab (Ravu)
The global, randomized Phase III COMMODORE 1 study showed similar safety and exploratory efficacy for crovalimab▼ vs eculizumab in randomized patients who received prior eculizumab treatment; this study also enrolled non-randomized patients who switched from ravulizumab to crovalimab▼. This poster reports efficacy and safety data from the COMMODORE 1 ravulizumab switch cohort, with a median treatment duration of approximately 2 years.
Haematology Paroxysmal Nocturnal Hemoglobinuria AAMDSIF-2025
06:00 PM
Duration 90mins Maryland, USA
Phase III Randomized COMMODORE 1 Trial: 2-Year Safety and Efficacy of Crovalimab▼ in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Switched From Eculizumab
Phillip Scheinberg, Diego Villa Clé, Berangere Devalet, Valentina Giai, Cristina Barrenetxea Lekue, Hsuan-Yu Lin, Zsolt Nagy, Jun-ichi Nishimura, Jens Panse, Agnieszka Piekarska, Jorg Schubert, Kazutaka Sunam, Mustafa N. Yenerel, Anita Appius, Brittany Gentile, Shino Iwase, Himika Patel, Sasha Sreckovic, Austin G Kulasekararaj
Haematology | Paroxysmal Nocturnal Hemoglobinuria

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 90mins Maryland, USA
Phase III Randomized COMMODORE 2 Trial: 2-Year Efficacy and Safety of Crovalimab▼ in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Naive to Complement Inhibition
Phillip Scheinberg, Alexander Röth, Guangsheng He, Andres Brodsky, Chatree Chai-Adisaksopha, Narcisa Sonia Comia, Anna Gaya, Martin Höglund, Richard J Kelly, Ahlam Naila Kori, Je-Hwan Lee, Naoshi Obara, Antonio Risitano, Anita Appius, Leigh Beveridge, Brittany Gentile, Sasha Sreckovic, Zilu Zhang, Bing Han
Haematology | Paroxysmal Nocturnal Hemoglobinuria

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 90mins Maryland, USA
Phase III COMMODORE 1 Trial: 2-Year Efficacy and Safety of Crovalimab▼ (Crova) in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Switched from Ravulizumab (Ravu)
Phillip Scheinberg, Hazzaa Alzahrani, Alejandro Contento Gonzalo, Martin Höglund, Jin Seok Kim, Jens Panse, Melissa J Rose, Jorg Schubert, Yasutaka Ueda, Eng Soo Yap, Muriel Buri, Nicolo Compagno, Brittany Gentile, Sasha Sreckovic, Austin G Kulasekararaj
Haematology | Paroxysmal Nocturnal Hemoglobinuria

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.